A novel, orally active alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL-10 deficient CD4(+) T cells in mice
Type
Retraction
Notice date
8/14/2012 0:00
Journal
The Journal of Pharmacology and Experimental Therapeutics
Publisher
ASPET: American Society for Pharmacology and Experimental Therapeutics